87 related articles for article (PubMed ID: 17257075)
1. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs.
Smith BF; Curiel DT; Ternovoi VV; Borovjagin AV; Baker HJ; Cox N; Siegal GP
Cancer Biother Radiopharm; 2006 Dec; 21(6):601-6. PubMed ID: 17257075
[TBL] [Abstract][Full Text] [Related]
2. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.
Le LP; Rivera AA; Glasgow JN; Ternovoi VV; Wu H; Wang M; Smith BF; Siegal GP; Curiel DT
Gene Ther; 2006 Mar; 13(5):389-99. PubMed ID: 16292351
[TBL] [Abstract][Full Text] [Related]
3. Productive replication of human adenovirus type 5 in canine cells.
Ternovoi VV; Le LP; Belousova N; Smith BF; Siegal GP; Curiel DT
J Virol; 2005 Jan; 79(2):1308-11. PubMed ID: 15613357
[TBL] [Abstract][Full Text] [Related]
4. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
[TBL] [Abstract][Full Text] [Related]
5. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
6. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies.
Alcayaga-Miranda F; Cascallo M; Rojas JJ; Pastor J; Alemany R
Cancer Gene Ther; 2010 Nov; 17(11):792-802. PubMed ID: 20671769
[TBL] [Abstract][Full Text] [Related]
7. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
8. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
9. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
10. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients.
Agarwal P; Gammon EA; Sandey M; Lindley SS; Koehler JW; Matz BM; Smith AN; Kashentseva EA; Dmitriev IP; Curiel DT; Smith BF
Heliyon; 2021 Feb; 7(2):e06210. PubMed ID: 33615011
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.
van Beusechem VW; Mastenbroek DC; van den Doel PB; Lamfers ML; Grill J; Würdinger T; Haisma HJ; Pinedo HM; Gerritsen WR
Gene Ther; 2003 Nov; 10(23):1982-91. PubMed ID: 14528322
[TBL] [Abstract][Full Text] [Related]
13. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
14. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of antibodies against canine adenovirus (CAV) type 2 in domestic dog populations in South Africa precludes the use of CAV-based recombinant rabies vaccines.
Wright N; Jackson FR; Niezgoda M; Ellison JA; Rupprecht CE; Nel LH
Vaccine; 2013 Aug; 31(38):4177-82. PubMed ID: 23867013
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
17. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
[TBL] [Abstract][Full Text] [Related]
18. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein.
Le LP; Li J; Ternovoi VV; Siegal GP; Curiel DT
J Gen Virol; 2005 Dec; 86(Pt 12):3201-3208. PubMed ID: 16298964
[TBL] [Abstract][Full Text] [Related]
19. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
Graat HC; Witlox MA; Schagen FH; Kaspers GJ; Helder MN; Bras J; Schaap GR; Gerritsen WR; Wuisman PI; van Beusechem VW
Br J Cancer; 2006 Jun; 94(12):1837-44. PubMed ID: 16736005
[TBL] [Abstract][Full Text] [Related]
20. Production and purification of non replicative canine adenovirus type 2 derived vectors.
Szelechowski M; Bergeron C; Gonzalez-Dunia D; Klonjkowski B
J Vis Exp; 2013 Dec; (82):50833. PubMed ID: 24326926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
